EUVIMEDEUVIMED entdecken
KorrekturOpen Access · CC BY 4.0

Correction: Effect of preexisting human leukocyte antigen donor-specific antibodies especially human leukocyte antigen-DQ on kidney transplant outcome

Sonia Mehrotra, Raj Kumar Sharma, Rakesh Kapoor, Rajesh Kumar Jaiswal, Rohit Kapoor

Frontiers in Nephrology · 30.06.2026 · 6

DOI: 10.3389/fneph.2026.1864478 ↗

Kurz gefasst

Korrektur in der Zeitschrift Frontiers in Nephrology, online erschienen am 30.06.2026. Verfasst von Sonia Mehrotra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology & Immunology, Medanta Super Speciality Hospital, Lucknow, Uttar Pradesh, India. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney transplantation remains the gold-standard treatment for patients with end-stage renal disease (ESRD), offering improved survival, quality of life, and cost-effectiveness compared to long-term dialysis.(1) However, long-term graft survival is threatened by immune-mediated complications, most notably antibody-mediated rejection (AMR), which is strongly associated with donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) (2). DSAs may arise due to prior sensitization events such as pregnancy, blood transfusion, or previous transplants, or may develop de novo after transplantation (3). Among the various HLA loci, antibodies targeting HLA-DQ antigens have emerged as clinically significant due to their high immunogenicity, prolonged persistence in circulation, and strong association with chronic allograft injury (4,5).Recent epidemiological data have shown the increasing recognition of HLA-DQ antibodies as key mediators in transplant immunobiology (6). Studies from single-and multicentre cohorts suggest that anti-DQ donor-specific antibodies (DSAs) constitute up to 55%-70% of all de novo DSAs detected post-transplant. These antibodies are more frequently implicated in biopsy-proven AMR, transplant glomerulopathy, and long-term graft dysfunction compared to DSAs against HLA-A, HLA-B, or HLA-DR antigens (7). Despite advances in histocompatibility testing and desensitization strategies, class II DSAs--particularly anti-HLA-DQ-remain a major therapeutic challenge. (8,9) These antibodies often persist in circulation, are relatively resistant to conventional therapies such as plasmapheresis, intravenous immunoglobulin (IVIG), and rituximab; and frequently exhibit high mean fluorescence intensity (MFI) values (10). Elevated MFI has been shown to correlate with adverse immunological outcomes. Moreover, unlike class I DSAs, class II antibodies display delayed clearance and may persist even after apparent clinical resolution of rejection episodes, further complicating long-term management (11).In current transplant practice, most allocation systems and risk stratification models focus on panel reactive antibody (PRA) levels, prior sensitization, and donor-specific antibody mean fluorescence intensity (DSA MFI) thresholds but do not always distinguish between DSA classes or specificities. As such, clinical protocols may inadequately address the unique risks posed by HLA-DQ mismatches and antibodies. This gap is particularly concerning given accumulating evidence that anti-DQ DSAs, both preformed and arising de novo, are independently associated with inferior graft survival. The present study was therefore undertaken to evaluate the clinical impact of pre-transplant DSA class and specificity, with a focused analysis on anti-HLA-DQ antibodies, in a real-world cohort of live donor kidney transplant recipients.This was a prospective, observational cohort study conducted at Medanta Kidney and Urology Institute, Lucknow, a tertiary referral center for renal transplantation, between January 2020 and December 2022.This study was conducted in order to evaluate the impact of preexisting donor-specific anti-HLA antibodies, with a special focus on anti-HLA-DQ antibodies, on clinical outcomes in kidney transplant recipients, particularly in the setting of ABO-incompatible transplants and under standardized desensitization and induction immunosuppression protocols.Pre-transplant HLA sensitization screening was conducted in 119 prospective kidney transplant recipients. Live donor kidney transplantation was performed in 100 patients, who were included in the final analysis and followed for a minimum of 4 years post-transplant. Among these patients, 19 (19%) underwent ABO-incompatible (ABOi) transplants.All recipients underwent panel reactive antibody (PRA) screening and single antigen bead (SAB) assay using the LIFECODES ® Single Antigen Assays (LSA) by Immucor-Werfen to detect IgG class I and class II anti-HLA antibodies, including anti-HLA-DQ. DSA positivity was defined as an MFI greater than 1,000. Throughout the manuscript, MFI ranges are uniformly reported from higher to lower values to reflect the maximum observed antibody strength. Complement-dependent cytotoxicity crossmatch (CDCXM) was performed in all patients and yielded negative results in every recipient. Flow cytometric crossmatch (FCXM) was positive for T cells in three cases and showed borderline reactivity for B cells in one case. Patients undergoing ABO-incompatible or HLAincompatible transplantation received desensitization therapy according to institutional protocol. For ABO-incompatible transplants, desensitization was initiated with alternate-day plasmapheresis or immunoadsorption and continued until anti-A or anti-B isoagglutinin titers were reduced to ≤1:8, with titers monitored before each session and on the day of transplant. In HLA-incompatible transplants, alternate-day double filtration plasmapheresis (DFPP) was employed to reduce DSA MFI levels below 1,000. In both groups, intravenous rituximab (200 mg) was administered 2 weeks prior to the scheduled transplant date as preconditioning.All recipients received standardized immunosuppressive therapy according to institutional protocols. For induction, patients were administered either anti-thymocyte globulin (ATG; Thymoglobulin ® ) at a dose of 1.5 mg/kg intravenously on postoperative day (POD) 0 and POD 2, or anti-human Tlymphocyte immunoglobulin (Grafalon ® ) at 3.0 mg/kg intravenously on the same schedule, based on clinician discretion. Intraoperatively, all patients received methylprednisolone 500 mg intravenously, followed by hydrocortisone 100 mg intravenously every 8 h beginning on POD 0. Maintenance immunosuppression included oral tacrolimus initiated at 0.05 mg/kg/day following pre-transplant rituximab administration and continued postoperatively (Table 1). Methylprednisolone 500 mg x 3 doses. Antithymoglobulin, 1.5 mg/kg x 7-14 days.Mycophenolate sodium (MMF-S) was started at 360 mg twice daily during the desensitization phase and escalated to 750 mg twice daily after transplantation. Prednisolone tapering was performed postoperatively in accordance with institutional guidelines. Patients were followed longitudinally for up to 48 months post-transplant. Primary outcome analyses were performed at 24 months, while extended follow-up up to 48 months was used to capture late rejection episodes and long-term graft outcomes. The primary outcome was the incidence of biopsy-proven acute rejection (BPAR), classified according to the Banff 2019 criteria. Secondary outcomes included graft function [estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula], graft survival, delayed graft function (DGF), patient survival, and infectious complications.Descriptive statistics were used to summarize demographic and clinical characteristics. Continuous variables were expressed as mean ± standard deviation (SD), and categorical variables were presented as frequencies and percentages. Comparisons between groups (e.g., DSA-positive vs. DSA-negative; ABO-compatible vs. ABO-incompatible) were performed using the chi-square test for categorical variables and Student's t-test or Mann-Whitney U test for continuous variables, as appropriate. A pvalue of 5,000, irrespective of antigen specificity. While our single high-risk case aligns with prior reports linking very high MFI to acute rejection, the available data are insufficient to support a blanket recommendation to avoid living-donor transplantation in all such situations. Instead, we suggest that preformed DSA with MFI >5000 should be considered a very high-risk immunologic profile, prompting individualized decision-making, intensified desensitization, and close post-transplant surveillance.This study has important limitations. Only one recipient developed biopsy-proven AMR, limiting the ability to perform meaningful statistical analysis regarding the impact of preformed class II DSA. Although primary analyses were performed at 24 months, extended follow-up up to 48 months may still be insufficient to fully assess late chronic antibody-mediated injury or long-term graft survival differences between DSA-positive and DSA-negative recipients. Larger multicenter studies with longer duration of follow-up are required to validate these observations.In this cohort, a single early antibody-mediated rejection episode occurred in a recipient with high-MFI preformed HLA-DQ DSA who underwent ABO-incompatible transplantation. While the coexistence of high-titer DQ DSA and ABO incompatibility provides a biologically plausible context for AMR, the available data are insufficient to support a statistical association or causal inference. The observation, therefore, suggests a potential immunologic risk pattern rather than a confirmed relationship. Careful pre-transplant evaluation of DSA specificity and antibody strength, particularly for HLA-DQ, together with individualized immunosuppression and close post-transplant monitoring, remains essential. Future studies with larger sample sizes and longer follow-up are needed to clarify the true impact of preformed DQ DSA and to determine whether HLA-DQ matching should be systematically incorporated into allocation policies.

Schlagwörter

Stichwörter der Autor:innen

ATLGHLA-DQ antibodiesantibody-mediated rejectiondonor-specific antibodieskidney transplantationsingle antigen bead assay

Autor:innen und Institutionen

  • Department of Molecular Biology & Immunology, Medanta Super Speciality Hospital, Lucknow, Uttar Pradesh, India.
  • Department of Nephrology and Kidney Transplant Medicine, Medanta Super Speciality Hospital, Lucknow, Uttar Pradesh, India.
  • Department of Kidney Transplant and Urology Institute, Medanta Super Speciality Hospital, Lucknow, Uttar Pradesh, India.

Zitieren

APA

Mehrotra, S., Sharma, R. K., Kapoor, R., Jaiswal, R. K., & Kapoor, R. (2026). Correction: Effect of preexisting human leukocyte antigen donor-specific antibodies especially human leukocyte antigen-DQ on kidney transplant outcome. Frontiers in Nephrology, 6. https://doi.org/10.3389/fneph.2026.1864478

Vancouver

Mehrotra S, Sharma RK, Kapoor R, Jaiswal RK, Kapoor R. Correction: Effect of preexisting human leukocyte antigen donor-specific antibodies especially human leukocyte antigen-DQ on kidney transplant outcome. Frontiers in Nephrology. 2026;6. doi:10.3389/fneph.2026.1864478

BibTeX
@article{Mehrotra2026,
  author = {Mehrotra, Sonia and Sharma, Raj Kumar and Kapoor, Rakesh and Jaiswal, Rajesh Kumar and Kapoor, Rohit},
  title = {Correction: Effect of preexisting human leukocyte antigen donor-specific antibodies especially human leukocyte antigen-DQ on kidney transplant outcome},
  journal = {Frontiers in Nephrology},
  year = {2026},
  volume = {6},
  doi = {10.3389/fneph.2026.1864478}
}
Kostenlos starten →